Drug intelligence / Profile preview

ChAdOx1 RVF

Development stage: Phase 2
Lead developer: University of Oxford
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

ChAdOx1 RVF is a vaccine candidate for Rift Valley fever (RVF), a zoonotic mosquito-borne viral disease. It utilizes the ChAdOx1 adenovirus vector platform expressing the RVF viral Gn and Gc glycoproteins. The vaccine is designed with a One Health approach for use in both humans and livestock, having demonstrated safety and immunogenicity in Phase I trials and 100% efficacy against wild-type RVF virus challenge in animal studies.

Beyond the preview

Go deeper on ChAdOx1 RVF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChAdOx1 RVF.

Explore the full profile